Shamma Rattan Booth

Policy Advisor at Alzheimer's Research UK, interested in early detection, prevention and diagnosis. 🍊

[Shamma Rattan Booth @RattanShamma]

Action on cancer is urgent. It takes two minutes!

I've emailed my candidates asking them to make this election a #TurningPointForCancer. Will you join me by emailing yours? https://t.co/FB0jSOS2L5

[Shamma Rattan Booth @RattanShamma]

Please take a moment to donate! https://t.co/B3viM3tGVe

[Shamma Rattan Booth @RattanShamma]

Please take a moment to donate! https://t.co/B3viM3tGVe

[Alzheimer's Research UK @AlzResearchUK]

Martin, who is a volunteer on our Policy Insight & Experience Panel, is living with posterior cortical atrophy, a rare form of dementia.

He has written about his experience and why he believes it's never too early to get a diagnosis.
https://t.co/AGY6DZsKst

[AMRC @AMRC]

🩺Great news that a new treatment is showing potential benefit to patients with Alzheimer’s - take a look at this animation from @AlzResearchUK on what the next steps might look like for bringing the therapy to patients ⬇️

[We're not on X anymore – formerly @PifOnline @PiFonline]

Almost 1 million people in England took part in @NIHRresearch projects in 2022-23. Numbers were up on pre-pandemic levels with an extra 1,300 people a week taking part in research. The data relates to Clinical Research Network portfolio studies: https://t.co/OrR0AjyZnf

[🟧 Hilary Evans-Newton 🟧 @HilaryAlzUK]

Today's news is further proof that research is working.
We will continue to work tirelessly on behalf of people affected by dementia, to make sure any treatments can be made available without delay #foracure

[David Thomas @david_rt84]

Exciting news! What needs to happen next? UK regulators need to review this data ASAP to judge whether treatment is safe & effective. NHS needs to make big improves in how it diagnoses Alzheimer's disease. And we need to increase the momentum of research to build on this.🧠

[David Thomas @david_rt84]

More good news from across the pond. Really important @MHRApress reviews this drug to judge its safety and effectiveness as a matter of urgency.

[Alzheimer's Research UK @AlzResearchUK]

🚨 The @US_FDA has granted full approval for Alzheimer’s drug lecanemab.🚨

This news should serve as a wake-up call to get the @NHSuk ready for new medicines like #lecanemab.

Our Chief Exec @HilaryAlzUK reacts 👇

[BookTrust @Booktrust]

Disadvantaged children are growing up without books of their very own. Without books that they can love and cherish. And without a favourite bedtime story that they want to read again and again. Become a BookTrust Friend and help us reach more children with the magic of reading.

[Greg Smith MP @gregsmith_uk]

We're on the cusp of the first generation of treatments for Alzheimer's Disease, but there's a great deal to do to prepare the UK for new dementia treatments. Grateful to @AlzResearchUK Head of Policy Dr Susan Mitchell for coming to Parliament to brief MPs on these developments.

[Alzheimer's Research UK @AlzResearchUK]

Thanks to progress in research, we’re on the cusp of a new era in dementia.

But bringing new treatments into routine use will be challenging. The Major Conditions Strategy presents a huge opportunity to address these challenges & transform our health system 👇

[Cancer Research UK @CR_UK]

It’s #InternationalNursesDay and today we’re highlighting some of our incredible nurses!

Read the thread below as we spotlight Caroline, a cancer information nurse specialist, and Trevor, a clinical trials patient information nurse specialist 👇🧵 1/3

[Shamma Rattan Booth @RattanShamma]

@deliriumkrish Paneer!

[Alzheimer's Research UK @AlzResearchUK]

Did you know people with and without a dementia diagnosis are needed to take part in dementia research?

Find out more about getting involved 👇🏽
https://t.co/IpJFZ1eo6I

[Nature is Amazing ☘️ @AMAZlNGNATURE]

Blue tit singing on a cold early morning you can see its song in the air 😀

📸: Mikhail Kalinin

[Alzheimer's Research UK @AlzResearchUK]

We're at a tipping point in dementia research. But we must not let the system in place for delivering new treatments fall behind the science.

Our Chief Exec @HilaryAlzUK spoke to @hannahdev @guardianscience about the future of dementia treatments 👇
https://t.co/Wxv0P6yNiP

[🟧 Hilary Evans-Newton 🟧 @HilaryAlzUK]

Great to speak to ⁦@hannahdev⁩ about the strides we’re making in dementia research and my hopes as Chair of the Dementia Mission.
https://t.co/tTKlSKYYqo